Effects of Antiprogestins on the Uterus

Sophie Ouzounian, Philippe Bouchard, Nathalie Chabbert-Buffet, Nathalie Chabbert‐Buffet
Women's health (London, England) · 2008 · vol. 4(3) , pp. 269–280 · doi:10.2217/17455057.4.3.269 · PMID:19072476 · W2143232485
review OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Progesterone-receptor modulators have applications in women's health but long-term use is limited by concerns about endometrial safety.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progesterone-receptor modulators (PRMs) are progesterone-receptor ligands that can exert agonistic, antagonistic or mixed agonist-antagonist effects depending on the cellular context. The mechanisms of action of these compounds are still incompletely understood. PRMs already have several applications in women's health such as emergency contraception, pregnancy termination, management of early fetal demise and cervical maturation. The main indications that will be developed in the future include dysfunctional bleeding and preoperative treatment of uterine myomas. Other future indications may include estrogen-free contraception, treatment of endometriosis and prevention and treatment of breast cancer. However, the available data from mid- to long-term continuous administration studies has raised the issue of endometrial safety. For this reason, long-term applications of PRMs are currently postponed, although windows of treatment with a short course of progestin therapy, or even by a short interruption of treatment, could improve endometrial aspects if needed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hormone Antagonists Progestins Receptors, Progesterone Receptors, Progesterone Uterus Animals Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Female Hormone Antagonists Humans Leiomyoma Leiomyoma Metrorrhagia Metrorrhagia Mifepristone Mifepristone Progestins Receptors, Progesterone Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK